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Abstract
Translational oncology represents a bridge between basic research and clinical practice in cancer medicine. Today,
translational research in oncology benefits from an abundance of knowledge resulting from genome-scale studies
regarding the molecular pathways involved in tumorigenesis. In this Forum article, we highlight the state of the art
of translational oncology in five major cancer types. We illustrate the use of molecular profiling to subtype colorectal
cancer for both diagnosis and treatment, and summarize the results of a nationwide screening program for ovarian
cancer based on detection of a tumor biomarker in serum. Additionally, we discuss how circulating tumor DNA can
be assayed to safely monitor breast cancer over the course of treatment, and report on how therapy with immune
checkpoint inhibitors is proving effective in advanced lung cancer. Finally, we summarize efforts to use molecular
profiling of prostate cancer biopsy specimens to support treatment decisions. Despite encouraging early successes,
we cannot disregard the complex genetics of individual susceptibility to cancer nor the enormous complexity of the
somatic changes observed in tumors, which urge particular attention to the development of personalized therapies.
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Introduction
Tommaso A. Dragani (Fig. 1)
The term “translational oncology” first appeared in the
scientific literature about 15 years ago [1, 2], although this
field has a longer history, as it was the paradigm for trans-
lational research in general. The concept of translational
research emerged from the US National Cancer Institute at
the 1992 National Conference on Cancer Prevention and
Early Detection, where James L. Mulshine and colleagues
discussed how epithelial cancers could be blocked in the
early stages of tumorigenesis if agents were developed to
interfere with growth factors or other molecules involved
in tumor promotion: ‘Through this type of translational re-
search, important applications of molecular biology may
greatly improve the success of preventative strategies for
cancer control’ [3]. Shortly afterwards, George D. Demetri,
from the Dana-Farber Cancer Institute, wrote ‘research
and clinical development of hematopoietic cytokines has
been a magnificent example of “bench to bedside” transla-
tional research’ [4].
As translational research established itself as a bridge
between basic research and clinical practice, its applica-
tion spread beyond cancer to disease in general and then
to non-biomedical fields such as engineering. This latter
development required an update of terminology within
the biomedical community. Thus, the term ‘translational
medicine’, which had been used occasionally in the 1990s
(e.g., [5]), became established in medical discourse upon
the 2003 founding of the Journal of Translational Medicine.
In its wake, dozens of journals on translational research
were founded in a myriad of disciplines of biomedi-
cine, including cancer research, for which it acquired
a new term – translational oncology. While this field
has been the pathfinder for translational research over
the past 25 years, there has been ‘a remarkable acceleration
in the pace of translational cancer medicine’ in the past
decade thanks to the availability of powerful ‘molecular
characterization technologies’ [6].
One exciting focus of translational oncology today is
immunotherapy, where the combination of basic re-
search on tumor cell biology and technological advances
in immune cell engineering is permitting the development
of therapeutic antibodies and cancer vaccines. Cancer
immunotherapy was chosen as the ‘advance of the year’
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for 2016 by the American Society of Clinical Oncology
(ASCO) because ‘[i]n just a few short years, researchers
and regulators have moved several different immunother-
apy strategies from bench to bedside’ [7]. Highlighted in
the ASCO report are the monoclonal antibody drugs
ipilimumab, nivolumab and pembrolizumab, which func-
tion as immune checkpoint inhibitors that enhance the
body’s immune response to tumors, as well as novel
approaches to boost the ability of T cells to detect and
destroy cancer. One of these approaches involves the ad-
ministration of a therapeutic cancer vaccine that delivers
tumor antigen, with the aim of priming and activating
tumor-specific T cells.
The field of vaccine-based immunotherapy is soon to
receive an enormous boost by Cancer MoonShot 2020, a
coalition of biotech and pharmaceutical companies,
medical universities, and other institutions in the United
States (US), sponsored and funded by the US govern-
ment [8]. The project aims to drive drug discovery by
enrolling 20,000 patients with 20 tumor types in clinical
trials, with the goal of developing effective cancer cures
by 2020. Proponents of the program argue that a well-
funded effort will succeed in its mission, just as the US
succeeded in sending astronauts to the Moon in 1969.
Others are more cautious, arguing that eliminating cancer
is more complex than space travel, because cancer is not a
single disease and individual tumors are not homogeneous
entities [9].
The complexity of cancer is ever more apparent with
every new discovery. Genome-wide association studies
have shown that only a small fraction of an individual’s
risk for cancer can be predicted by their genetic consti-
tution, and that hundreds of genetic variants conspire to
determine that risk [10]. Often, disease-related genetic
variants do not alter protein-coding regions of the gen-
ome, and evidence is emerging to show that they influence
cell physiology by altering non-coding RNAs with gene-
regulatory roles [11]. Additional layers of complexity have
emerged from the sequencing of cancer genomes. These
efforts have revealed large intra-individual heterogeneity
in neoplasms of the same organ and histotype, i.e., each
tumor has its own mutational profile (for lung cancer,
see [12]). Additionally, they have uncovered substantial
intra-tumoral heterogeneity that complicates treatment
decisions and calls into question the strategy of genotyp-
ing tumoral DNA using a single biopsy [13]. Altogether,
this new understanding of cancer complexity is the driving
force in the development of diagnostic tests for the
molecular profiling of tumors, which may guide the choice
of suitable personalized therapies for each patient.
This Forum article illustrates how these efforts in
translational oncology are unraveling in five major can-
cers – colorectal, ovarian, breast, lung, and urological
cancers. In each section, the authors highlight what they
see as the most important breakthrough from transla-
tional oncology in their field.
 Antoni Castells reports on colorectal cancer (CRC),
highlighting how gene expression profiling allowed
the identification of four molecular subtypes, one of
which is susceptible to immunotherapy with
pembrolizumab; molecular profiling in this cancer
also facilitated the development of a diagnostic test
that detects tumor DNA in stool.
 Vathany Kulasingam and Eleftherios P. Diamandis
discuss a large, longitudinal United Kingdom
screening program for ovarian cancer (OvCa)
involving serum measurements of a tumor
biomarker, namely carbohydrate antigen 125;
although the cost-effectiveness of this program is yet
to be defined, the program created a biobank that
will support translational research from the clinic
back to the laboratory.
 Helena Earl reports on breast cancer, pointing to the
many biomarkers already used to inform therapeutic
Fig. 1 Tommaso A. Dragani. Tommaso A. Dragani is Director of the
Research Unit of Genetic Epidemiology and Pharmacogenomics at
Fondazione IRCCS Istituto Nazionale dei Tumori in Italy. He has been
a pioneer of research on the genetic predisposition to cancer. His
early studies in animal models led to the identification and
characterization of chromosomal loci that determine the inherited
predispositions to liver, lung and skin tumorigenesis. He has since
extended this research to humans by carrying out population-based
case-control studies to identify genetic polymorphisms associated
with the risk for and prognosis of lung cancer, thus contributing to
the field of complex (polygenic) genetic predisposition to cancer.
Dr. Dragani’s research group discovered the mechanism underlying
the association between polymorphisms in nicotinic receptor subunit
genes and the risks of both lung cancer and nicotine dependence.
Additionally, he led the first genome-wide pharmacogenomic study
on pain relief, which discovered that multiple loci modulate the
response to opioid therapy for cancer pain
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decision-making and highlighting “liquid biopsy”
(i.e., assay for circulating tumor DNA in blood) as a
non-invasive way to monitor changes in a tumor’s
genetic profile and response to therapy.
 Wade T. Iams and Christine M. Lovly report recent
advances in lung cancer research, focusing on
oncogene-driven targeted therapy and immune
checkpoint inhibitors that have changed the survival
expectations for patients with advanced disease.
 J.P. Michiel Sedelaar and Jack A. Schalken discuss
recent milestones in prostate cancer research,
highlighting how whole exome and transcriptome
sequencing of biopsy specimens generated “clinically
actionable information” about genomic aberrations
in the majority of investigated patients.
Overall, this Forum highlights the state of the art of
translational research in oncology, demonstrating several
clinical successes but also disclosing areas in which further
in-depth bench-to-bedside-and-back research is needed to
increase the accuracy of early diagnoses, reduce therapy-
and disease-related side effects, and improve the quality of
life of patients during treatment.
Translational advances in colorectal cancer (CRC)
research
Antoni Castells (Fig. 2)
CRC is one of the most prevalent cancers in Western
countries and the second cause of cancer-related deaths
worldwide [14], both of which justify considering CRC a
major healthcare problem. However, from an academic
perspective, its relevance goes beyond these figures, as it
is a paradigm of translational oncology. Indeed, there are
very few neoplasms, if any, in which research has been
translated into clinical practice so rapidly and efficiently,
thus continuously modifying our approach to the diag-
nosis, treatment and prevention of the disease.
In the last few decades, tremendous advances have been
achieved in the characterization of most molecular mech-
anisms involved in colorectal carcinogenesis. Indeed, three
pathways of genetic instability, namely chromosomal in-
stability, microsatellite instability (MSI), and methylation,
have been identified as being responsible for both sporadic
and inherited CRC forms [15, 16]. Although several key
investigations had uncovered some of the critical genes
implicated in these pathways (i.e., APC, KRAS, TGF-β,
TP53, PIK3CA, and DNA mismatch-repair (MMR) genes),
a fully integrated view of the genetic and genomic changes
and their significance for colorectal tumorigenesis was
lacking until the Cancer Genome Atlas project reported a
comprehensive molecular view [17]. This extraordinary ef-
fort, using different genome-scale approaches (i.e., exome
sequence, DNA copy number, promoter methylation, and
messenger RNA and microRNA expression), has contrib-
uted to the classification of 15 % of these tumors as hyper-
mutated (three-quarters of them exhibiting MSI, usually
with hypermethylation and MLH1 silencing, and one-
quarter with somatic MMR gene and POLE mutations)
[17]. Excluding these hypermutated cases, CRC tumors
were found to have considerably similar patterns of gen-
omic alteration; 24 genes were significantly mutated and,
in addition to those in the expected APC, TP53, SMAD4,
PIK3CA, and KRAS genes, other frequent mutations were
observed in ARID1A, SOX9 and FAM123B [17]. There is
little doubt that results of this seminal investigation have
enabled a deeper understanding of CRC pathophysiology
and will definitely contribute to the identification of new
therapeutic targets.
CRC, as other neoplasms, is a disease with heteroge-
neous outcomes and drug responses [18]. On the other
hand, it is widely accepted that gene expression-based
subtyping is a valuable approach for patient stratification.
In the last few years, different molecular CRC classifica-
tions have been proposed with the final goal of advancing
towards a more personalized medicine. However, their im-
pact on clinical practice has been scarce, mainly because
of their discrepant results. To resolve these inconsistencies
and facilitate clinical translation, an international consor-
tium dedicated to large-scale data sharing has made con-
siderable effort to coalesce six independent classification
systems into four consensus molecular subtypes with
distinguishing features: MSI immune (hypermutated,
microsatellite unstable, and strong immune activation),
canonical (epithelial, marked WNT and MYC signaling
Fig. 2 Antoni Castells. Antoni Castells is Associate Professor at the
University of Barcelona, School of Medicine. He is a specialist in
gastroenterology, and since 2016, has been Medical Director of the
Hospital Clinic of Barcelona. His professional activity has been related
to colorectal cancer, involving its diagnosis, therapeutics and prevention,
being Coordinator of the Colorectal Cancer Unit and Co-coordinator of
the Barcelona Colorectal Cancer Screening Program. His research
achievements are mainly derived from two internationally-recognized
studies, the EPICOLON and COLONPREV projects, in which he is leading
principal investigator
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activation), metabolic (epithelial and evident metabolic
dysregulation), and mesenchymal (prominent TGF-β
activation, stromal invasion and angiogenesis) [19]. This
new classification approach based on well-differentiated
biological profiles may represent a landmark for future
clinical stratification and subtype-based targeted interven-
tions [18].
An example of how advances in basic science are revo-
lutionizing the therapeutic approach to CRC is the re-
cent demonstration of MSI as predictor of a favorable
response to immunotherapy in patients with advanced
neoplasms [20]. Indeed, these authors hypothesized that
tumors with a large number of somatic mutations due to
MMR defects (those exhibiting MSI) were susceptible to
immune checkpoint blockade. Using pembrolizumab, an
anti-programmed death 1 immune checkpoint inhibitor, it
has been possible to demonstrate an increased progression-
free survival (hazard ratio (HR), 0.10; P < 0.001) and overall
survival (HR, 0.22; P = 0.05) in patients with MMR-
deficient CRC with respect to those with MMR-proficient
lesions [20]. This beneficial effect was not limited to pa-
tients with CRC, but also extended to other MMR-deficient
tumors, thus emphasizing the fact that advances in one
particular type of cancer can be extrapolated to other
neoplasms sharing the same underlying molecular
mechanism. It is important to keep in mind, however, that
molecular profiling cannot entirely replace conventional
tumor classification based on organ site. In fact, a recent
study evaluating the usefulness of vemurafenib in patients
with various BRAF V600-mutated non-melanoma cancers
demonstrated that this oncogene seems to be targetable in
some, but not all, tumors [21].
Besides targeting therapeutics, molecular profiling may
also have potential for CRC screening, a preventive
approach to reduce the burden of this disease on health-
care systems. Indeed, the utility of this strategy has been
accepted by the European Commission, which encourages
the implementation of screening programs throughout
Europe [22]. Recommended CRC screening strategies
fall in two broad categories: stool tests (i.e., fecal immuno-
chemical testing (FIT) for occult blood) that primarily
detect cancer, and structural exams (i.e., flexible sigmoid-
oscopy, colonoscopy and CT-colonography), which are
effective in detecting both cancer and premalignant
lesions. Whereas FIT is predominant in Europe and
Australia, colonoscopy is the dominant screening mo-
dality in the US [23]. Very recently, a new non-invasive,
molecular-based strategy has been added to the first
category [24]. In this seminal study, a multi-target
stool DNA test (which includes quantitative molecular
assays for KRAS mutations, aberrant NDRG4 and BMP3
methylation, and β-actin, as well as a hemoglobin im-
munoassay) was superior to FIT in terms of sensitivity for
detecting CRC (92.3 % vs. 73.8 %, respectively; P = 0.002)
and, more importantly, advanced precancerous lesions
(42.4 % vs. 23.8 %, respectively; P < 0.001), albeit at the ex-
pense of a lower specificity (89.8 % vs. 96.4 %, respectively;
P < 0.001) [24].
Finally, an understanding of the genetics of inherited
CRC is also important to identify at-risk individuals and
to consequently improve diagnostic and therapeutic
strategies among gene carriers. Indeed, familial predis-
position occurs in approximately 25 % of patients with
CRC, being hereditary syndromes with a known genetic
defect responsible for up to 5 % of all these tumors [15,
16]. In such a context, genetic testing, thus far, has been
performed in a phenotype-driven manner [25]. However,
the availability of multigene panels for hereditary cancer
risk assessment that allow for next-generation sequen-
cing of numerous genes in parallel is changing the
current approach [26]. Although the benefits of such
comprehensive testing strategies are still under debate,
there are few doubts that they have arrived to stay.
To screen or not to screen for ovarian cancer
(OvCa) – results of UKCTOCS study
Vathany Kulasingam and Eleftherios P. Diamandis
(Figs. 3 and 4)
OvCa is the most lethal gynecological malignancy, ac-
counting for 5–6 % of all cancer-related deaths. As with
any cancer, the notion of earlier OvCa diagnosis and
population screening is an attractive but challenging
proposition; OvCa has low prevalence (0.1 %), which
means that, to be of clinical relevance, a screening test
must have a positive predictive value of > 10 %, with a
specificity of > 99.6 % and a sensitivity of > 75 %. In
addition, since OvCa lacks a recognizable latent phase,
overdiagnosis, misdiagnosis, and creation of a false sense
of security are some of the potential adverse effects of
screening. Using prostate-specific antigen as a screening
test for prostate cancer as an example, two large ran-
domized prospective trials have been completed and it is
still unclear whether the benefits outweigh the harms in
this setting [27]. On the contrary, screening for cervical
cancers has resulted in a significant (50–90 %) reduction
in disease-specific mortality.
Based on the World Health Organization’s 10 princi-
ples of screening [28] (including, but not limited to, the
disease being an important health problem as well as ap-
propriate treatment and a suitable test acceptable to the
population being available), population screening for
OvCa is warranted. The ability to detect human malig-
nancy via a simple blood test has long been an objective
in medical screening. The advantages of such an easy to
use, relatively non-invasive and operator-independent
test are self-evident. A variety of ovarian tumor markers
have been studied; the most extensively investigated of
these being carbohydrate antigen 125 (CA125), a large
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glycoprotein of unknown function. Since its discovery in
1981 by Bast, Jr. et al [29], CA125 still remains the gold-
standard serum biomarker for OvCa. As such, a handful
of OvCa screening trials have been undertaken, including
the ovarian arm of the Prostate, Lung, Colorectal, Ovarian
(PLCO) Cancer Screening trial (USA) [30]. The PLCO
trial was a randomized controlled trial (RCT) of approxi-
mately 68,000 post-menopausal women, of whom ap-
proximately 30,000 underwent screening between 1993
and 2007. The women were screened using serum CA125
with a single cut-off of ≥ 35 kU/L and transvaginal ultra-
sound for 4 years followed by CA125 alone for a further
2 years. The results showed no reduction in mortality.
However, by far the largest RCT has been the UK
Collaborative Trial of Ovarian Cancer Screening (UKC-
TOCS), whose primary objective was to assess the effect
of screening on disease mortality [31]. We believe that this
effort, undertaken by Jacob et al., represents one of the
most important translational advances in OvCa research.
Over 1.2 million women were recruited from 13 regional
centers in England, Wales and Northern Ireland over the
course of approximately 4 years, starting in 2001, with ap-
proximately 200,000 post-menopausal women being ran-
domly assigned in a 1:1:2 ratio to annual multimodal
screening (MMS) with serum CA125 interpreted with the
risk of OvCa algorithm (ROCA) and with transvaginal
ultrasound (USS), annual USS alone, or no screening. The
study was powered to detect a mortality reduction of
30 %. At a median 11 years’ follow-up, OvCa was diag-
nosed in 0.7 % of women in the MMS group versus 0.6 %
in each of the USS and no screening groups. The primary
outcome analysis spanning 0–14 years showed no signifi-
cant reduction in mortality in the MMS and USS groups
(15 % and 11 %) when compared to the no screening arm.
Nonetheless, a secondary sub-group analysis did show the
benefit of screening in women between the latter half of
the screening period (years 7–14), when prevalent cases
Fig. 4 Eleftherios P. Diamandis. Eleftherios P. Diamandis is currently
Professor and Head, Division of Clinical Biochemistry, Department of
Laboratory Medicine and Pathobiology, University of Toronto,
Biochemist-in-Chief at University Health Network, and Division Head
of Clinical Biochemistry at Mount Sinai Hospital, Toronto. He is also a
“Hold’em for Life” Chair on Prostate Cancer Biomarkers, a Corresponding
Member of the Academy of Athens, a Member of the Royal Society of
Canada and the Canadian Academy of Health Sciences, and an elected
Fellow of the American Association for the Advancement of Science
Fig. 3 Vathany Kulasingam. Vathany Kulasingam completed her PhD
at the Department of Laboratory Medicine and Pathobiology, University
of Toronto. Following her PhD, she completed a post-doctoral training
diploma program in Clinical Chemistry at the University of Toronto.
Dr. Kulasingam is currently a clinical biochemist at the University Health
Network in Toronto, an Assistant Professor at the Faculty of Medicine,
University of Toronto, and a Fellow of the Canadian Academy of Clinical
Biochemistry. Her current interests include novel tumor biomarker
discovery and application of proteomics to clinical practice
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were excluded (28 % mortality reduction after 7 years of
screening in the MMS group). The authors state that this
is due to the late effect on mortality that is seen in screen-
ing trials and that additional follow-up of the UKCTOCS
cohort is necessary before “firm conclusions” can be
reached on the efficacy and cost-effectiveness of OvCa
screening.
One key difference between the UKCTOCS study and
other OvCa screening trials is in the interpretation of
serum CA125. UKCTOCS used ROCA – an algorithm
that compares the CA125 profile (not just a single cut-
off value) of cases to that of healthy women and incor-
porates age-specific incidence of OvCa in calculating risk
[32]. Using ROCA, the study triaged women to normal
(annual screening), intermediate (repeat CA125 in
3 months), and elevated (repeat CA125 and perform
USS). However, a post-hoc analysis of the PLCO cohort
using ROCA as the screening modality showed that it
would not have produced a statistically significant mor-
tality reduction effect [33].
Despite the modest reduction in mortality in the UKC-
TOCS trial, the authors have to be given credit for con-
ducting a large scale RCT of this magnitude over the
course of approximately 15 years. More than 200,000
participants, > 650,000 annual screening events, a multi-
center setting, and strong quality assurance programs for
standardization of ultrasound findings are some of the
highlights of the RCT study design. Further, the fact that
they were able to achieve 99 % compliance on follow-up
certainly deserves applause. In addition, a side, and argu-
ably one of the most important, benefits to arise from this
exercise is the biorepository they now possess – longitu-
dinal samples with excellent, linked clinical data that can
serve as a useful resource for a broad research community
to investigate the prevention, early detection, etiology, and
treatment of OvCa. Additional follow-up ancillary studies
and evaluation of the cohorts with different cut-off values
or groups may also be examined, ultimately serving as a
rich data-mining resource.
Translational breast cancer research – past
success and future promise
Helena Earl (Fig. 5)
Translational cancer research provides a “bridge”
between fundamental scientific research and clinical
research, often referred to colloquially as “bench-to-bed-
side”. Scientific cancer researchers, on the one hand, and
clinical researchers, on the other, pursue their academic
tracks with passion and precision, each in their own in-
creasingly complex environment. So what of the “transla-
tional research” bridge? To follow the analogy, a physical
bridge is designed by a team of highly trained structural
engineers, to last for centuries carrying constant heavy
traffic. The equivalent translational cancer research
structure, at present, would be more equivalent to a
high-wire act or, at best, a single track, one-way, wob-
bly construction, suspended between mountain tops!
It is time to construct a robust, state-of-the-art trans-
lational bridge, built to last.
The cultural challenges in bringing together the scien-
tific and clinical research groups in a meaningful dialogue
are considerable; there needs to be mutual understanding
and respect across the bridge, which is sensitive to the en-
deavors on both sides. The recent journal debate around
more public access to clinical trials data has been timely
[34]. Clinical trials data, painstakingly collected and ana-
lyzed, clearly need to be published fully, including that of
negative or inconclusive studies. Nevertheless, the high
quality clinical data from trials should remain the asset of
researchers who have devoted their careers to developing,
Fig. 5 Helena Earl. Helena Earl is an academic clinician in Medical
Oncology and currently Professor of Clinical Cancer Medicine at the
University of Cambridge, Department of Oncology and a Principal
Investigator of the NIHR Cambridge Biomedical Research Centre and
Cambridge Experimental Cancer Medicine Centre. She is co-lead for
the Breast Cancer Programme at the Cancer Research UK Cambridge
Cancer Centre and significantly contributes to the translational endeavor
in precision medicine and the development of personalized treatment
pathways in breast cancer. In Cambridge, she is the cancer lead in the
collaborative workstream for novel adaptive trial designs
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running, and analyzing these clinical trials. Clearly, with
appropriate safeguards, these data can be shared, along
with the translational samples being increasingly collected
within large phase 3 clinical trials [35]. Thus, a sensitive
partnership can be developed to move forward – without
the clinical research effort in trials, there would be less
high-quality data, with allied translational tumor and
germline banks for scientists to investigate.
So, in the translational effort, could large clinical trials
be replaced by ‘big data’ national and international
collections from breast cancer populations? Whilst the
short answer is ‘yes’, tumor and germline cancer genomics
collections are now being developed, and will enable trans-
lational research to be carried out routinely within cancer
centres. Undoubtedly, the advantages of clinical trial-based
translational research will remain. These include more
homogeneous populations of patients, treated in a standard
way, with excellent governance of treatment delivery, pa-
tient safety, follow-up, and short- and long-term outcomes
analyses. Routine data collection in cancer clinics/centres
will have to become an order of magnitude better to re-
place the data available within clinical trials, and apart from
other challenges, will incur considerable cost.
Translational breast cancer research includes past suc-
cess and enormous future potential and has been at the
forefront of this field. The ultimate goal is the application
of precision medicine and personalized breast cancer care
to all patients. Notable successes include biomarkers of
treatment response in routine clinical use such as ER, PR,
HER2, and Ki67. A large number of predictive biomarkers
of response to targeted, novel agents are emerging, al-
though there remain considerable challenges in terms of
the robustness of these in the clinic. Many large phase 3
breast cancer clinical trials have translational collections
that have been utilized for translational research in terms
of tumor biomarkers [35], germline predisposition to
breast cancer and association with prognosis [36], and
pharmacogenetics [37]. Phase 2 breast cancer trials have
embedded a rich seam of translational research and, in
this context, ‘window’ studies carried out pre-operatively
are being utilized [38]. The neoadjuvant context has been
a translational treasure trove, likely to lead to the more
rapid introduction of novel therapies with significant
translational discovery [39]. Breast cancer researchers have
led the field with the discovery and validation of tumor
genomic stratification [40, 41] and plasma circulating
tumor DNA (ctDNA) in both metastatic [42] and early
breast cancer [43].
There are two recent advances in breast cancer transla-
tional research that deserve particular mention. The first
is the outstanding work of the METABRIC (Molecular
Taxonomy of Breast Cancer International) Consortium
[40], which was the first to discover and validate 10
clusters of breast cancer stratified by long-term breast
cancer-specific survival, an important recent advance in
translational breast cancer research. This analysis was car-
ried out on 2000 breast cancers, collected in fresh tissue
tumor banks and funded within an international consor-
tium. The same group has recently refined this dataset
with the definition of somatic tumor mutations in a total
of 2500 fresh breast tumors [41]. This detailed transla-
tional research will inform not only breast cancer progno-
sis within the 10 groups, but also the underlying biology
of these novel stratifications of breast cancer. In addition,
this will allow the potential to utilize these to predict re-
sponse not only to novel targeted small molecule therap-
ies, but also an increasing number of novel immune
therapies through both antibody and vaccine treatments.
These novel stratified groups have been defined from the
start with access to the clinical follow-up data and, inevit-
ably, the advances achieved will have important impact
and treatment outcomes on patients with breast cancer.
The second is the use of ctDNA to track mutations
and response to treatment in both metastatic [42] and
neo/adjuvant breast cancer [43]. The forefront transla-
tional research in Cambridge, UK has been important to
define and integrate ctDNA into clinical/translational re-
search in metastatic breast cancer. Following the original
descriptions of rapid biomarker response to treatment
defined in the seminal publication [41], ctDNA is now
being embedded into study designs. Further elegant re-
search demonstrates the ability to track specific mutations
present in the primary tumor [43], which now offers the
potential to include ctDNA tracking into the design of
novel feasibility studies due to start in 2016. In the near
future, the use of ctDNA as a repeatable “liquid biopsy”
will become a reality, allowing translational and clinical re-
searchers the potential of a dynamic tracking of tumor
heterogeneity and the distinct possibility of personalizing
precision treatments for patients in real time.
Recent advances in translational lung cancer
research
Wade T. Iams and Christine M. Lovly (Figs. 6 and 7)
Lung cancer is the leading cause of cancer deaths
worldwide [44]. More than 85 % of lung cancers are
classified as non-small cell lung cancer (NSCLC), as de-
fined by histologic features. NSCLC can be divided into
several subtypes, of which adenocarcinoma is the most
common, comprising over 50 % of all lung cancers [45].
Although histological features currently remain the basis
of clinical diagnosis, advances in molecular oncology
have allowed researchers to identify oncogenes and
therapeutic targets in NSCLC such as epidermal growth
factor receptor (EGFR). Tremendous progress has been
made in advancing the diagnosis and treatment of pa-
tients with lung cancer. The progress in translational
lung cancer research over the past 5 years can be divided
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into four broad categories: (1) new treatments for pa-
tients with acquired resistance to molecular-targeted
therapy; (2) ongoing development of ctDNA (also known
as “liquid biopsy”) technology for clinical use; (3) a
dramatic surge in the number of clinical trials involving
immune checkpoint inhibitors; and (4) early progress in
novel therapies for patients with small cell lung cancer
(SCLC). We will highlight demonstrative examples from
each of these areas of translational research in lung cancer
to illustrate the direction of the field.
On November 13, 2015, the United States Food and
Drug Administration (FDA) granted accelerated approval
to osimertinib for the treatment of patients with NSCLC
harboring an EGFR T790M mutation. Mutations in EGFR
are detected in approximately 30–40 % of Asian patients
and 10 % of Caucasian patients with NSCLC [46]. While
initial therapy targeting this mutation is quite effective,
drug resistance typically develops within 1–2 years [46].
The EGFR T790M “second site” mutation is the most
common resistance mechanism, affecting 60 % of patients
with EGFR-mutant NSCLC that has acquired resistance to
EGFR-targeted therapy [46]. Osimertinib is the first FDA-
approved drug for patients with acquired resistance to the
FDA-approved EGFR tyrosine kinase inhibitors erlotinib,
gefitinib and afatinib. Whereas erlotinib, gefitinib and afa-
tinib were designed against wild-type EGFR, osimertinib
was specifically designed to be selective for mutant EGFR,
thereby increasing the precision of our therapies [46]. The
approval of this drug demonstrates that targeting resist-
ance mechanisms is a successful paradigm for ongoing
Fig. 6 Wade Iams. Wade Iams has recently completed his Chief
Residency at Vanderbilt University Medical Center, and is beginning
his clinical fellowship in hematology/oncology at McGaw Medical
Center of Northwestern University. He is an active member of the
American Society of Clinical Oncology (ASCO), International Association
of Lung Cancer Research (IASLC), and the American Association for
Cancer Research (AACR), where he also serves on the Associate
Member Fundraising Committee. He has been awarded a Young
Investigator Award from Adaptive Biotechnologies as well as travel
awards from the AACR and IASLC for early-career research on
thoracic malignancies
Fig. 7 Christine M. Lovly. Christine M. Lovly is an Assistant Professor of
Medicine and Cancer Biology at Vanderbilt University Medical Center.
Dr. Lovly is a physician-scientist with a special interest in thoracic
malignancies. Her laboratory research is directed at understanding and
developing improved therapeutic strategies for specific clinically
relevant molecular subsets of lung cancer. Dr. Lovly has received
independent grant funding from several foundations, including
Uniting Against Lung Cancer, Conquer Cancer Foundation, LUNGevity,
Damon Runyon Foundation, and V Foundation. She is an active
member of the American Society of Clinical Oncology (ASCO), the
International Association for the Study of Lung Cancer (IASLC), and
the American Association for Cancer Research (AACR). She is also
co-editor-in-chief for the website www.mycancergenome.org, a
Vanderbilt initiated, freely available website which aims to provide
health care practitioners, patients and advocates with up-to-date
information regarding genetically informed cancer medicine
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research to improve outcomes in lung cancer patients
with mutant EGFR and other known oncogenes, such as
the ALK and ROS1 genes.
As the monitoring of dynamic changes in oncogene
mutations takes on greater therapeutic importance,
developing technology to screen patients for these changes
without repeating invasive tumor biopsies is critical. Ac-
cordingly, on the same day that osimertinib’s FDA approval
was announced, the FDA also announced approval of the
first companion diagnostic test to detect EGFR T790M
mutations in blood (Cobas EGFR mutation test v2); this is
one example of many assays designed and optimized
to detect ctDNA in plasma. The clinical application
of this technology represents the progress of nearly a
decade of research into strategies to monitor specific lung
cancer mutations in the bloodstream and, in some cases,
bloodstream mutation monitoring has detected resistance
mutations up to 4 months prior to radiographic progres-
sion on oncogene-targeted therapy [47, 48]. As specific
oncogene mutation-directed therapies proliferate, clinic-
ally applicable assays to detect these mutations are being
developed in lockstep, such that lung cancer care is rap-
idly becoming not only genomically personalized, but is
doing so in a dynamic manner. ctDNA testing has the po-
tential to revolutionize not only how we diagnose and
treat lung cancer, but other solid organ tumors as well.
No discussion of translational research advances in
lung cancer would be complete without noting the success
and burgeoning clinical trial landscape applying immune
checkpoint inhibitors in varying combinations to treat
lung cancer patients. Harnessing a patient’s immune sys-
tem to destroy malignant cells has been a treatment goal
for decades [49]. However, not until March 2015 were any
specific immune system activators FDA-approved to treat
lung cancer (Fig. 8). Currently, two immune checkpoint
inhibitors (both inhibitors of programmed death-1) have
been approved for the treatment of patients with advanced
NSCLC – nivolumab (FDA approved March 4, 2015) and
pembrolizumab (FDA approved October 2, 2015) [50].
Many ongoing clinical trials seek to combine immune
checkpoint inhibitors with additional immune modulatory
agents, chemotherapy or targeted therapy. As a single ex-
ample, the ongoing CheckMate 227 trial (NCT02477826)
[51] will enroll patients with previously untreated ad-
vanced NSCLC and stratify them into four arms, namely
chemotherapy alone, nivolumab alone, nivolumab com-
bined with ipilimumab (an immune checkpoint inhibitor
of cytotoxic T lymphocyte antigen 4), and nivolumab
combined with chemotherapy. The combination of differ-
ent immune checkpoint inhibitors seeks to increase effi-
cacy by addressing more than one pathway through which
tumors evade the immune system, and the combination of
2004 – FDA approval of erlotinib for 
2nd line treatment of NSCLC. 
2011 – FDA approval of crizotinib for 
ALK-rearranged NSCLC. 
2013 – FDA approval of erlotinib for 
1st line treatment of EGFR-mutant  
NSCLC. 
2015 – FDA approval of osimertinib 
for EGFR T790M mutant NSCLC. 
2016 – FDA approval of crizotinib for 
ROS1-rearranged NSCLC.
Cytotoxic Chemotherapy
1978 – FDA approval of  
cisplatin.
Mid-1990’s – Paclitaxel, 
docetaxel, vinorelbine, and 
gemcitabine proven effective, 
particularly with platinum-
based therapy.
2005 – FDA approval of   
bevacizumab (first survival 
benefit in patients with 
advanced lung cancer). 
2009 – FDA approval of 
pemetrexed for non-squamous 
NSCLC.
Oncogene Targeted Therapy














































2015 – FDA approval of nivolumab 
Fig. 8 Advances in the treatment of patients with lung cancer over the past 50 years. Advances in the treatment of patients with lung
cancer over the past 50 years can be divided into cytotoxic chemotherapy, oncogene-targeted therapy and immunotherapy, with the
most recent advances being in oncogene-targeted therapy and immunotherapy. All FDA approvals noted apply to patients with locally
advanced or metastatic lung cancer
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immune checkpoint inhibitors with chemotherapy seeks
to capitalize on the antigenic stimulation of tumor cell
apoptosis induced by chemotherapy. As an example of the
combination of immune checkpoint inhibitors and onco-
gene mutation-targeted therapy, the TATTON clinical
trial (NCT02143466) assessed the combination of osimerti-
nib and durvalumab (an immune checkpoint inhibitor of
programmed death ligand 1) in patients with EGFR-mutant
NSCLC. This trial sought to target the oncogenic driver
mutation in these patients while simultaneously promoting
immune recognition during tumor apoptosis. Initial
results from this trial have shown an increased inci-
dence of pneumonitis in the combination therapy arm
[52]. This example strikes an important cautionary
note regarding the potential increased toxicities asso-
ciated with combining different agents. These adverse
events, as well as the so-called “financial toxicity” of these
very expensive therapies (for example, using nivolu-
mab to treat metastatic renal cell carcinoma has been
shown to cost patients and insurers at least $65,000
[53]), bring to the forefront the need to rationally de-
sign clinical trials by understanding the molecular
mechanisms underpinning response or resistance to
these agents. Optimal translational research using
clinical trials data will most safely and efficiently ad-
vance the field of implementation of these new treat-
ment modalities.
While NSCLC is the most common form of lung can-
cer, 15 % of patients with lung cancer have SCLC. Pa-
tients with this disease have not seen a change in
therapy for over 30 years [54]. The success of nivolu-
mab and pembrolizumab in patients with NSCLC has
spurred clinical trials of each agent in patients with
SCLC (NCT01928394 and NCT02054806, respectively).
Not only immune checkpoint inhibitors, but molecu-
larly targeted therapies are being assessed in clinical tri-
als in patients with SCLC. Delta-like protein 3 is an
inhibitor of neuroendocrine cell differentiation prefer-
entially expressed in patients with SCLC compared to
control patients [55]. An inhibitor of Delta-like protein
3, Rovalpituzumab Tesirine, is being tested in an on-
going clinical trial (NCT02674568). These clinical trials
demonstrate the potential for treatment improvements
in the near future for patients with this recalcitrant
malignancy.
While lung cancer remains the most lethal malignancy
worldwide, the success of oncogene-driven targeted ther-
apy and immune checkpoint inhibitors has already chan-
ged the landscape of survival for patients with advanced
disease. As the aforementioned translational research ad-
vances indicate, the field is rapidly progressing through
paradigm shifting techniques; physicians should be aware
of the recent improvements in outcomes for patients with
this disease.
Recent breakthroughs in translational prostate
cancer research
J.P. Michiel Sedelaar and Jack A. Schalken (Figs. 9 and 10)
With the abundance of scientific work in the field of
oncological urology, it is very hard to distinguish the
most important recent translational advances in uro-
logical cancer research. When do you consider science
to be a real clinical game changer, in comparison to
basic research work which in itself explains small steps
in an oncological phenomenon, but in fact can lead (by
serendipity sometimes) to breakthroughs? Even the fact
that a paper may be considered a milestone is often sub-
ject to a difference of opinions. Nevertheless, we high-
light herein four papers that, in our opinion, represent
groundbreaking advancements in translational research.
One of our major considerations for candidates for these
milestones in translational research would be the imme-
diate impact on the direct translation of the presented
findings into clinical practice. The selected papers were
published in high impact journals within the last
18 months. Non-surprisingly, all papers are the fruit of
labor from well-established international and multidis-
ciplinary research teams.
The first paper to be discussed as a game changer in
the field of personalized prostate cancer care is that by
Robinson et al. [56]. The group presents their work on a
multi-institutional clinical sequencing infrastructure to
Fig. 9 J.P. Michiel Sedelaar. J.P. Michiel Sedelaar is the deputy-chief
of the department of Urology at Radboud University Medical Center,
Nijmegen, the Netherlands. He finished his urology training in 2007
and in 2008–2009 he was a post-doc researcher at the Johns Hopkins
Medical Institutes in Baltimore, MD, USA. His focus during that time
was the development of smart-drugs for detection and treatment of
prostate cancer and steroidogenesis of prostate cancer. Since 2010, he
returned to Nijmegen for an onco-urology staff position. His research
achievements are mainly on imaging studies for prostate cancer
(use of MRI, MRI-guided treatments) and basic research on the
androgen receptor in prostate cancer. He has national and international
board functions; among others, he is the chair of the EAU-Young
Urology Office
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conduct prospective whole-exome and transcriptome
sequencing of bone or soft tissue tumor biopsies from
a cohort of 150 castration-resistant prostate cancer
(CRPC)-affected individuals. CRPC is the terminology
used for patients with prostate cancer who progress
despite the use of hormonal treatment. Even with the
combination of luteinizing hormone releasing hormone
analogs and the anti-androgen blockade, patients progress
on prostate-specific antigen (PSA) level, symptoms and/or
imaging. In these patients, the androgen receptor (AR) is
still a major driver of prostate cancer. The authors de-
scribe several known and new aberrations in the genome.
Aberrations of AR ETS genes, TP53 and PTEN, were fre-
quent, with, not surprisingly, enriched TP53 and AR alter-
ations in metastatic CRPC compared to primary prostate
cancer. New genomic alterations were found in PIK3CA/
B, R-spondin, BRAF/RAF1, APC, β-catenin, and ZBTB16/
PLFZ. Aberrations in BRCA2, BRCA1 and ATM were ob-
served at substantially higher frequencies compared to
those in primary prostate cancers. Of all patients, 89 %
harbored a clinically actionable aberration, mostly in the
AR (62.7 %) and in other cancer-related genes (65 %), and
8 % with actionable pathogenic germline alterations. This
multi-institutional group concluded that the cohort study
provides the clinically actionable information that could
impact treatment decisions for these patients. The find-
ings underline the fact that CRPC is a general term used
for an accumulation of many different types of genomic
alterations in prostate cancer, which should all be treated
differently. This study provides prostate cancer clinicians
grounds for re-biopsy of their patients during the course
of the disease and treatment, in order to facilitate person-
alized medical treatment for their developing CRPC.
The next groundbreaking paper is that by Mateo et al.
[57], which indicates that the model proposed, i.e.,
precision medicine based on the molecular profile of the
cancer’s actionable targets, can be validated. This study
describes a phase 2 trial conducted in patients with
progressive metastatic CRPC (mCRCP) and treated with
olaparib. Olaparib is a new poly(adenosine diphosphate
[ADP]-ribose) polymerase (PARP) inhibitor. PARP is in-
volved in multiple aspects of DNA-repair and the PARP-
inhibitor olaparib has been approved for the treatment of
OvCa with BRCA1/2 mutations. PARP-inhibition has
durable antitumor activity in men with mCRPC and
deleterious germline BRCA2 mutations, a disease subset
of mCRPC associated with a poor prognosis [58]. Fifty eli-
gible patients had histologically confirmed mCRPC with
progression after chemotherapy. All patients were treated
with 2dd 400 mg olaparib. The primary endpoint was the
response rate, defined as a response according to RECIST
criteria, or a PSA-decrease of 50 % or more, or a conver-
sion in the circulating tumor-cell count from > 5/7.5 mL
to < 5/7.5 mL. For all patients, biomarker studies were
prospectively planned. Of the 49 evaluated patients, 16
had a response to olaparib with a median duration of
treatment of 40 weeks. Overall, 16 patients (33 %) had
tumor aberrations in DNA-repair genes. Patients with ab-
errations in DNA-repair genes had a significantly higher
response to olaparib. Specifically, the seven patients with
BRCA2-loss had PSA levels that fell by 50 % or more from
baseline. From these seven patients, the five with measur-
able disease also had a radiologic partial response. Further,
four out of five patients with deleterious ATM mutations
had a response to olaparib. The authors concluded that
the results of this phase 2 clinical trial suggest that a com-
mon subset of metastatic prostate cancers can be molecu-
larly stratified for treatment using high-throughput next
generation sequencing assays. Very much like Robinson et
al. [56], this paper underlines the need for re-biopsy of pa-
tients during the course of their disease in order to
achieve personalized treatment.
The last two breakthrough papers are discussed together,
since these have been published by the same research
group. Gao et al. [59] and Drost et al. [60] respond to the
lack of in vitro prostate cancer models that reflect the di-
versity in human prostate cancer. The authors describe the
Fig. 10 Jack A. Schalken. Jack A. Schalken trained as biochemist at
Radboud University Medical Center, Nijmegen, the Netherlands,
where he is Director of the urology research lab. His work focusses
on translational research, with an emphasis on biomarkers and novel
therapeutic targets such as epithelial–mesenchymal transition. His
team’s research led to the clinical introduction of the first urine-based
prostate cancer test (Progensa PCA3, 2006) and more recently to the
SelectMdX test, which has been commercially available for clinical use
since 2015. In 1996, he was appointed as full professor at the University
of Utrecht (experimental oncology), and in 2001 as professor of
experimental urology (Radboud University Medical Center). He has
been awarded several scientific awards, most recently the Dominique
Chopin award (2015) for his long-term contribution to the field
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development of a 3D-organoid system for long-term indi-
vidual culture of prostate cancer from biopsy specimens
and circulating tumor cells. The methodology described in
these manuscripts should enable the generation of a large
repertoire of patient-derived prostate cancer-lines amen-
able to genetic and pharmacologic studies. As the authors
explain, the past few years have seen a dramatic increase
in the number of approved therapies, with several promis-
ing investigational agents in late stage development for
mCRPC. The response to these novel agents, however, is
highly variable and only about 30 % of mCRPC patients
will attain a durable response of more than 6 months.
These models can be used to study the ever growing
number of approved therapies for mCRPC, the combin-
ation and sequencing of such therapies, and to predict pa-
tient response.
As stated above, the process of selecting game chan-
ging papers from such an enormous field of translational
prostate cancer studies will lead to other research mile-
stones being ignored. Nevertheless, aside from personal
opinion, the selected papers have also been recognized
by the research community as being groundbreaking.
Their common denominator is the acknowledgement of
the diversity of genomic alterations in mCRPC and the
need for a personalized treatment option for these pa-
tients. Using fresh tissue re-biopsy, circulating tumor cells
or 3D-organoid cell systems, the genomics of mCRPC can
be studied and responses to different therapies could even
be predicted. These studies have most definitely changed
the understanding of mCRPC and the methods through
which the ever expanding armamentarium of prostate
cancer treatments are selected for individual patients, thus
improving patient outcomes.
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